Abstract: Specifically useful stereoisomers of 1,3-dioxane derivatives are described and their use in the treatment of a disease or condition dependent on PPAR modulation, such as diabetes, cancer, inflammation, neurodegenerative disorders and infections as well as their use in the treatment of a disease related to TP, such as cardiovascular diseases.
Type:
Grant
Filed:
January 18, 2008
Date of Patent:
September 17, 2013
Assignee:
Evolva SA
Inventors:
Alexandra Santana Sorensen, Jean-Philippe Meyer, Peteris Alberts, Prathama S. Mainkar, Melya Hughes Crameri, Thierry Bonnaud, Joanne Kelleher, David Pearson
Abstract: A cis- or trans-stilbenoid of the general formula (1): in which each of R1, R2, R3, R4 and R5 is hydrogen or hydroxy, or a glycosylated or oligomeric form thereof, is produced by cultivating a micro-organism producing said stilbenoid, in a multi-phase system comprising at least an aqueous first phase containing said micro-organism and a second phase immiscible with said aqueous phase in which (e.g. as which) said stilbenoid accumulates. The second phase may be said stilbenoid or a free or encapsulated solvent compatible with the growth of the micro-organism, for instance an ester.
Type:
Grant
Filed:
July 25, 2008
Date of Patent:
August 27, 2013
Assignee:
Evolva Sa
Inventors:
Hans Peter Schmidt, Michael Katz, Bo Stenhuus, Jochen Förster
Abstract: The present invention relates to compounds containing 1,3-dioxane moiety, pharmaceutical compositions thereof, and the use of the compounds and compositions for the modulation of thromboxane A2 or a peroxisome proliferator-activated receptor. The compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention of cancer.
Type:
Application
Filed:
March 8, 2013
Publication date:
August 1, 2013
Applicant:
Evolva Sa
Inventors:
Alexandra Santana Sorensen, Jean-Philippe Meyer, Peteris Alberts, Mainkar S. Prathama
Abstract: The present invention relates to prodrugs of compounds containing 1,3-dioxane moiety, pharmaceutical compositions thereof, and the use of the compounds and compositions for the modulation of thromboxane A2 or a peroxisome proliferator-activated receptor. The prodrugs of the compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention of cancer.
Type:
Grant
Filed:
January 18, 2008
Date of Patent:
July 16, 2013
Assignee:
Evolva SA
Inventors:
Peteris Alberts, Alexandra Santana Sorensen
Abstract: The present invention relates to compounds containing 1,3-dioxane moiety, pharmaceutical compositions thereof, and the use of the compounds and compositions for the modulation of thromboxane A2 or a peroxisome proliferator-activated receptor. The compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention of cancer.
Type:
Application
Filed:
June 18, 2012
Publication date:
October 4, 2012
Applicant:
EVOLVA SA
Inventors:
Alexandra Santana Sorensen, Jean-Phillippe Meyer, Peteris Alberts, Mainkar Prathama
Abstract: The present invention relates to compounds containing 1,3-dioxane moiety, pharmaceutical compositions thereof, and the use of the compounds and compositions for the modulation of thromboxane A2 or a peroxisome proliferator-activated receptor. The compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention of cancer.
Type:
Application
Filed:
January 18, 2008
Publication date:
June 7, 2012
Applicant:
EVOLVA SA
Inventors:
Alexandra Santana Sorensen, Jean-Philippe Meyer, Peteris Alberts, Mainkar S. Prathama
Abstract: The present invention relates to combinatorial gene expression libraries and methods for making these. Such libraries are useful in discovery of novel and/or enhanced metabolic pathways leading to the production of novel compounds for e.g., drug discovery and/or to the prosecution of known compounds in novel quantities or in novel compartments of the cells. The expression libraries in particular are composed of host cells capable of co-ordinated and controllable expression of large numbers of heterologous genes in the host cells.
Type:
Application
Filed:
October 12, 2010
Publication date:
April 19, 2012
Applicant:
EVOLVA SA
Inventors:
Neil Goldsmith, Alexandra M.P. Santana Sørensen, Søren V.S. Nielsen
Abstract: A method of producing a low molecular weight organic compound (e.g. a plant or bacteria secondary metabolite) in increased yields involving use of a microorganism cell, which comprises a gene involved in the biosynthesis pathway leading to a low molecular weight organic aglycon compound and a glycosyltransferase gene capable of glycosylating the produced aglycon.
Type:
Grant
Filed:
October 21, 2010
Date of Patent:
January 31, 2012
Assignee:
Evolva SA
Inventors:
Joergen Hansen, Thomas Hvid Andersen, Finn Thyge Okkels
Abstract: A method of producing a low molecular weight organic compound (e.g. a plant or bacteria secondary metabolite) in increased yields involving use of a microorganism cell, which comprises a gene involved in the biosynthesis pathway leading to a low molecular weight organic aglycon compound and a glycosyltransferase gene capable of glycosylating the produced aglycon.
Type:
Application
Filed:
August 8, 2011
Publication date:
December 29, 2011
Applicant:
EVOLVA SA
Inventors:
Joergen Hansen, Thomas Hvid Andersen, Finn Thyge Okkels
Abstract: In the present invention are disclosed concatemers of concatenated expression cassettes and vectors that enable the synthesis of such concatemers. The concatemer comprises in the 5??3? direction a cassette of nucleotide sequence of the general formula [rs2-SP-PR-X-TR-SP-rs1]n wherein rs1 and rs2 together denote a functional restriction site, SP individually denotes a spacer of at least two nucleotide bases, PR denotes a promoter, capable of functioning in a cell, X denotes an expressible nucleotide sequence, TR denotes a terminator, and SP individually denotes a spacer of at least two nucleotide bases, and n>/=2, and wherein at least a first cassette is different from a second cassette. The main purpose of these concatemers is the controllable and co-ordinated expression of large numbers of heterologous genes in a single host. Furthermore, the invention relates to a concatemer of cassettes of nucleotide sequences and a method for preparing the concatemers.
Type:
Grant
Filed:
January 25, 2002
Date of Patent:
August 30, 2011
Assignee:
Evolva SA
Inventors:
Neil Goldsmith, Alexandra M. P. Santana Sorensen, Soren V. S. Nielsen, Michael Naesby
Abstract: 1,3-dioxane derivatives are described and their use in the treatment of a disease or condition dependent on PPAR modulation, such as diabetes, cancer, inflammation, neurodegenerative disorders and infections.
Type:
Application
Filed:
January 18, 2007
Publication date:
July 21, 2011
Applicant:
EVOLVA SA
Inventors:
Karsten Kristiansen, Prathama S. Mainkar, Jean-Philippe Meyer, Alexandra Santana Sorensen
Abstract: The present invention relates to combinatorial gene expression libraries and methods for making these. Such libraries are useful in discovery of novel and/or enhanced metabolic pathways leading to the production of novel compounds for e.g drug discovery and/or to the production of known compounds in novel quantities or in novel compartments of the cells. The expression libraries in particular are composed of host cells capable of co-ordinated and controllable expression of large numbers of heterologous genes in the host cells.
Type:
Grant
Filed:
January 25, 2002
Date of Patent:
November 23, 2010
Assignee:
Evolva SA
Inventors:
Neil Goldsmith, Alexandra M. P. Santana Sørensen, Søren V. S. Nielsen
Abstract: The present invention relates to compounds containing 1,3-dioxane moiety, pharmaceutical compositions thereof, and the use of the compounds and compositions for the modulation of thromboxane A2 or a peroxisome proliferator-activated receptor. The compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention of cancer.
Type:
Application
Filed:
January 18, 2008
Publication date:
October 28, 2010
Applicant:
EVOLVA SA
Inventors:
Alexandra Santana Sorensen, Jean-Philippe Meyer, Peteris Alberts, Mainkar S. Prathama
Abstract: Specifically useful stereoisomers of 1,3-dioxane derivatives are described and their use in the treatment of a disease or condition dependent on PPAR modulation, such as diabetes, cancer, inflammation, neurodegenerative disorders and infections as well as their use in the treatment of a disease related to TP, such as cardiovascular diseases.
Abstract: The present invention relates to prodrugs of compounds containing 1,3-dioxane moiety, pharmaceutical compositions thereof, and the use of the compounds and compositions for the modulation of thromboxane A2 or a peroxisome proliferator-activated receptor. The prodrugs of the compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention of cancer.
Type:
Application
Filed:
January 18, 2008
Publication date:
April 8, 2010
Applicant:
EVOLVA SA
Inventors:
Peteris Alberts, Alexandra Santana Sorensen